123 related articles for article (PubMed ID: 21204768)
1. Experimental study on the therapeutic effect of positron emission tomography agent [¹⁸F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model.
Fang S; Wang J; Jiang H; Zhang Y; Xi W; Zhao C; Tian M; Zhang H
Cancer Biother Radiopharm; 2010 Dec; 25(6):733-40. PubMed ID: 21204768
[TBL] [Abstract][Full Text] [Related]
2. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose.
Moadel RM; Weldon RH; Katz EB; Lu P; Mani J; Stahl M; Blaufox MD; Pestell RG; Charron MJ; Dadachova E
Cancer Res; 2005 Feb; 65(3):698-702. PubMed ID: 15705862
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer.
Moadel RM; Nguyen AV; Lin EY; Lu P; Mani J; Blaufox MD; Pollard JW; Dadachova E
Breast Cancer Res; 2003; 5(6):R199-205. PubMed ID: 14580255
[TBL] [Abstract][Full Text] [Related]
4. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of [
Gu B; Liu S; Sun Y; Zhang J; Zhang Y; Xu X; Yuan H; Wang M; Zhang Y; Yang Z
Mol Imaging Biol; 2019 Jun; 21(3):538-548. PubMed ID: 30218389
[TBL] [Abstract][Full Text] [Related]
6. Experimental study on the therapeutic effect and underlining mechanisms of positron in pancreatic cancer cells.
Wang Y; Li M; Diao R; Tung B; Zhang D; Li Y
Oncotarget; 2017 Aug; 8(31):51652-51662. PubMed ID: 28881676
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
8. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
9. The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Cheong SJ; Lee CM; Kim EM; Lim ST; Sohn MH; Jeong HJ
Nucl Med Biol; 2015 Feb; 42(2):85-91. PubMed ID: 25441255
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.
Hamann I; Krys D; Glubrecht D; Bouvet V; Marshall A; Vos L; Mackey JR; Wuest M; Wuest F
FASEB J; 2018 Sep; 32(9):5104-5118. PubMed ID: 29913554
[TBL] [Abstract][Full Text] [Related]
11. Quantitative correlation at the molecular level of tumor response to docetaxel by multimodal diffusion-weighted magnetic resonance imaging and [¹⁸F]FDG/[¹⁸F]FLT positron emission tomography.
Honndorf VS; Schmidt H; Wehrl HF; Wiehr S; Ehrlichmann W; Quintanilla-Martinez L; Barjat H; Ricketts SA; Pichler BJ
Mol Imaging; 2014; 13():. PubMed ID: 25430886
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis imaging probe predicts early chemotherapy response in preclinical models: A comparative study with 18F-FDG PET.
Song S; Xiong C; Lu W; Ku G; Huang G; Li C
J Nucl Med; 2013 Jan; 54(1):104-10. PubMed ID: 23283564
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake?
Mees G; Dierckx R; Vangestel C; Laukens D; Van Damme N; Van de Wiele C
Mol Imaging; 2013; 12(1):49-58. PubMed ID: 23348791
[TBL] [Abstract][Full Text] [Related]
15. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
16. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy.
Norregaard K; Jørgensen JT; Simón M; Melander F; Kristensen LK; Bendix PM; Andresen TL; Oddershede LB; Kjaer A
PLoS One; 2017; 12(5):e0177997. PubMed ID: 28542311
[TBL] [Abstract][Full Text] [Related]
18. Glucose metabolism gene expression patterns and tumor uptake of ¹⁸F-fluorodeoxyglucose after radiation treatment.
Wilson GD; Thibodeau BJ; Fortier LE; Pruetz BL; Galoforo S; Baschnagel AM; Chunta J; Oliver Wong CY; Yan D; Marples B; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):620-7. PubMed ID: 25304950
[TBL] [Abstract][Full Text] [Related]
19. Preclinical assessment of early tumor response after irradiation by positron emission tomography with 2-amino-[3-¹¹C]isobutyric acid.
Tsuji AB; Sugyo A; Sudo H; Suzuki C; Wakizaka H; Zhang MR; Kato K; Saga T
Oncol Rep; 2015 May; 33(5):2361-7. PubMed ID: 25813536
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
